Clinical Observation of Influence of Shibaweikeziliniaowan on Inflammatory Cytokines in Type 2 Diabetic Kidney Disease

© 2025 by the Author. Licensee Art and Design, USA. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution -Noncommercial 4.0 International License (CC BY-NC 4.0) ( https://creativecommons.org/licenses/by-nc/4.0/ )

Download PDF

Cite

XML

HTML

Abstract

Objective: To evaluate the impact of Shibaweikeziliniaowan on inflammatory cytokine profiles in patients with type 2 diabetic kidney disease (DKD). Methods: Sixty DKD patients were randomized equally into a control group (n=30) and a treatment group (n=30). Both cohorts received standard care and oral Dapagliflozin. The treatment group additionally received Shibaweikeziliniaowan. The intervention lasted eight weeks. Parameters measured pre- and post-treatment included urine microalbumin (mA1b), Urinary Albumin Creatinine Ratio (UACR), glycosylated hemoglobin A1c (HbA1c), tumor necrosis factor alpha (TNF-α), interleukin-1 (IL-1). Results: Post-treatment, both groups exhibited significant reductions in mA1b, UACR, TNF-α, and IL-1 levels (P < 0.05, P < 0.01). Inter-group comparisons revealed statistically significant differences favoring the treatment group (P < 0.05). Conclusion: Shibaweikeziliniaowan demonstrates efficacy in lowering inflammatory cytokines, suggesting a renal protective role in DKD management.

Keywords

Type 2 diabetes mellitus (T2DM)

Diabetic kidney disease (DKD)

Shibaweikeziliniaowan

Inflammation

Tibetan medicine

Dapagliflozin

Funding

This study is supported by the Natural Science Foundation of Tibet Autonomous Region (Project No.: [2022]66, XZ2022ZR-ZY39(Z)) ; This study is supported by the Shizhen Talent Program of Hubei Province for Scientific Research (Grant No.: Hubei Health Document [2024] No.256)

References

[1] Li Y, Teng D, Shi X, et al., 2020, Prevalence of Diabetes Recorded in Mainland China using 2018 Diagnostic Criteria from the American Diabetes Association: National Cross Sectional Study. BMJ, 2020(369): 997.

[2] American Diabetes Association, 2020, 11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes 2020. Diabetes Care, 2020(43): 135–151. https://doi.org/10.2337/dc20-S011

[3] Wu CC, Sytwu HK, Lin YF, 2012, Cytokines in Diabetic Nephropathy. Advances in Clinical Chemistry, 56(1): 55–74.

[4] Chinese Society of Diabetesology, 2021, Guidelines for the Prevention and Treatment of Type 2 Diabetes in China (2020 Edition). Chinese Journal of Diabetes, 13(4): 315–409.

[5] Packer M, Anker SD, Butler J, et al., 2020, Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. The New England Journal of Medicine, 383(15): 1413–1424.

[6] Neal B, Perkovic V, Mahaffey KW, et al., 2017, Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. The New England Journal of Medicine, 377(7): 644–657.

[7] Perkovic V, Jardine MJ, Neal B, et al., Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. The New England Journal of Medicine, 380(24): 2295–2306.

[8] Heerspink HJL, Stefansson BV, Correa-Rotter R, et al., 2020, Dapagliflozin in Patients with Chronic Kidney Disease. The New England Journal of Medicine, 383(15): 1436–1446.

[9] Luo GF, Zhang XF, 2008, Determination of Berberine Hydrochloride Content in Shibaweikeziliniaowan by HPLC Method. Qinghai Medical Journal, 38(8): 3.

[10] Zheng LL, Wang G, Wu Q, 2023, The Protective Effect of Shibaweikeziliniaowan on the Kidneys of Diabetic Nephropathy Rats. Chinese Traditional Patent Medicine, 45(1): 264–267.

[11] Liu AH, 2022, The Clinical Efficacy of the Shibaweikeziliniaowan in the Treatment of Diabetic Nephropathy. Journal of Medicine & Pharmacy of Chinese Minorities, 28(3): 24–25.

[12] Suonancuo, 2019, The Clinical Application Value of the Shibaweikeziliniaowan in the Treatment of Diabetes in Tibetan Medicine. World Latest Medicine Information, 19(56): 227–228.

[13] Liang PY, Yin LJ, Huaqiansangduo, et al., 2016, The Effect of Shibaweikeziliniaowan of Tibetan Medicine on Blood Sugar in Rats with High-Altitude Diabetes. Journal of Baotou Medical College, 32(12): 3–5.

[14] Peng C, Gao MS, Kong CX, et al., 2016, Clinical Observation of Influence of Yuquanwan Decoction on Inflammatory Cytokines in Type 2 Diabetic Kidney Disease. Journal of Nanjing University of Traditional Chinese Medicine, 32(2): 3.

[15] Purwata TE, 2011, High TNF-alpha Plasma Levels and Macrophages iNOS and TNF-alpha Expression as Risk Factors for Painful Diabetic Neuropathy. Journal of Pain Research, 4(1): 169–175.

[16] Vesey DA, Cheung C, Cuttle L, et al., 2002, Interleukin-1β Stimulates Human Mediators of Inflammation Renal Fibroblast Proliferation and Matrix Protein Production by means of a Transforming Growth factor-β-dependent Mechanism. Journal of Laboratory and Clinical Medicine, 2002(140): 342–350.

Previous article in this issue

Next article in this issue